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Background: Evidence indicates that there are no statistically significant differences in effectiveness among the airway clearance techniques
(ACTs) of active cycle of breathing, autogenic drainage, positive expiratory pressure (PEP) or oscillating PEP in the short-term, but are there
differences in the long-term (one year)? The objective of the study was to demonstrate non-inferiority in the long-term.
Methods: Seventy-five people with cystic fibrosis entered the prospective, randomised controlled trial of these five different ACTs. The primary
outcome measure was forced expiratory volume in one second (FEV1). Secondary outcome measures included exercise capacity and health related
quality of life.
Results: Using intention to treat, data were available on 65 subjects at the end of the study period. There were no statistically significant
differences among the regimens in the primary outcome measurement of FEV1 (p=0.35).
Conclusion: In different countries either one or several airway clearance regimens are used. This study provides evidence in support of current
practices.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Airway clearance techniques1. Introduction
The use of airway clearance techniques (ACTs) in chronic
suppurative lung disease is based on the hypothesis that
facilitation of the clearance of infected bronchial secretions
reduces the bacterial load in the airways, ‘has a major influence
in limiting the adult consequences of CF’ [1] and is felt to be of
benefit by the patient during a pulmonary exacerbation of
infection [2]. There are few clinicians and patients today who
would advocate a control arm of no airway clearance in the
presence of excess and infected bronchial secretions in people
with cystic fibrosis (CF). The literature contains many short-
term studies comparing one airway clearance regimen with⁎ Corresponding author. Department of Cystic Fibrosis, Royal Brompton
Hospital, London SW3 6NP, UK. Tel.: +44 20 7351 8041; fax: +44 20 7351
8052.
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doi:10.1016/j.jcf.2010.01.004another and a few longer term studies [3–5] but the regimens
used, especially in the short-term studies, have not always been
undertaken as advocated by the proponents.
The clinical signs and symptoms of respiratory disease in CF
are variable, but at some point cough becomes prominent, is
usually associated with sputum and respiratory failure is the
most common cause of death [6]. Cochrane reviews [7–10]
have concluded that airway clearance techniques have the short-
term effect of increasing mucus transport and there appears to
be no advantage of either ‘conventional’ chest physiotherapy or
oscillating devices over other airway clearance techniques in the
primary outcome measure of lung function, but there is little
evidence on which to draw conclusions concerning the long-
term effects. The objective of the current study was to
demonstrate non-inferiority in the long-term.
With improvements in health, quality of life and longevity
[11] in people with CF and the development of PEP and
oscillating PEP devices, airway clearance in the sitting positiond by Elsevier B.V. All rights reserved.
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In this study the airway clearance techniques (ACTs) of the
active cycle of breathing techniques (ACBT) [12], autogenic
drainage (AD) [13], positive expiratory pressure (PEP) [14] and
the oscillating PEP devices of the Flutter® (Flutter) [15] and R-
C Cornet® (Cornet) [16] were used in the sitting position and
compared over a period of one year. It was also hoped to
identify objective indicators as to when a particular regimen
should be recommended.
2. Methods
During formulation of the study proposal, the lead researcher
(JP) visited and worked with the internationally recognised
experts of the different airway clearance regimens: Jean
Chevaillier (AD, Belgium), Lynne Gumery (LG) (AD, United
Kingdom), Ulrich Cegla (Cornet, Germany), Jim Bolek (Flutter,
United States of America) and Mette Kelstrup (PEP, Denmark).
The lead researcher had been associated with the ACBT since
the 1960s. LG and Esta-Lee Tannenbaum (ET) trained the
subjects randomised to AD.
2.1. Subjects
All adult patients registered at Royal Brompton Hospital
with CF were considered for entry to the study.
Inclusion criteria: diagnosis of CF (genotype, sweat chlo-
ride concentration N60 mmol per litre or sweat sodium
concentration N70 mmol per litre), 16 years of age or over
and FEV1 of 25% predicted or greater on assessment for
entry to the study.
Exclusion criteria: evidence of a current respiratory
exacerbation [17], past history of pneumothorax, current
severe haemoptysis, awaiting lung/heart–lung transplanta-
tion, pregnancy and recent (within three months) acquisition
of Burkholderia cepacia.
2.2. Ethics
The study was approved by Royal Brompton & Harefield
NHS Trust and National Heart & Lung Institute Ethics
Committee. All subjects gave written, informed consent.
2.3. Randomisation
Randomisation was computerised and used a random
number sequence stratified by FEV1% predicted (FEV1 less
than 50%; FEV1 greater than or=50%) and sputum expecto-
rated (less than one cupful per day; greater than or=one cupful
per day). The subjects were randomised to one of the five
regimens of the ACBT, AD, Cornet, Flutter or PEP.
2.4. Treatment regimens
All treatments were undertaken in the sitting position and
independent of an assistant, but if a subject was to be admittedto hospital with an acute, infective pulmonary exacerbation, the
patient and the medical team were to optimise treatment, as
appropriate. For the study, the number of airway clearance
sessions in a day and the length of time for treatment was
individualised in agreement with each patient. One of the
researchers (JP, ET or LG) discussed and explained the regimen
to which the subject had been randomised. The subject practised
the technique, with the researcher/s, until he/she felt confident
to continue at home. Written instructions were given to each
subject with the regimens agreed and signed by the experts
above. When a device was used, cleaning of the device was
discussed, demonstrated and the instructions, approved by the
Infection Control Nurse at Royal Brompton Hospital, given to
the subject in writing.
2.5. Measurements
The primary outcome measure was forced expiratory volume
in one second (FEV1). Secondary outcome measures were:
– Other measures of lung function (forced vital capacity
(FVC), maximal expiratory flow at 25% of forced vital
capacity (MEF25) and residual volume as a percent of total
lung capacity (RV%TLC)
– Body mass index
– Modified shuttle test [18]
– Chronic respiratory questionnaire [19]
– Short form-36 registered with the Medical Outcomes Trust,
Boston, Massachusetts, USA
– Number of courses of intravenous antibiotics.
Subjects were requested to attend monthly, for a review of
their ACT and to record the outcome measurements. The
measurements of lung function and body mass index at 0, 6 and
12 months and the statistical analyses were undertaken by
observers (physiologists and statistician) blind to the regimen to
which the subjects had been randomised.
2.6. Statistical analysis
Sample size calculation was based on the only available data
at the time of setting up the study and was from short-term
airway clearance studies [12,20]. For 80% power and 5% level
of significance, 16 subjects would be required per group.
Intention to treat was used for the primary outcome measure of
FEV1.Mixedmodel analysis of variance (SAS®) was used in the
analysis of the data with comparisons made between two points
in time (0 months and 12 months) and among the five groups.
3. Results
3.1. Patient demographics
Four hundred and sixty-three adult patients with CF (aged
16 years and over) were registered at Royal Brompton Hospital
at the start of the study (Fig. 1). Of these 344 were within a
commutable distance of London or willing to travel. Two
Fig. 1. Study profile.
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entered the study. Reasons for not entering included participat-
ing in other studies, too busy with work or home commitments,
found to have contra-indications to entry, on the transplantation
waiting list, not contactable, transferred to another cystic
fibrosis centre and not interested. In addition to the 63, 12 newlyTable 1
Demographic data (n=75).
ACBT n=15
Age (years) Mean (±SD) 31.1 (±9.7)
Range: 17–52
Median (±Interquartile range) 30.0 (±16.0)
Sex Male: 11
73.3%
Female: 4
26.7%
FEV1 (litres) Mean (±SD) 2.0 (± 0.8)
Median (± Interquartile range) 1.6 (±1.3)
Median value SpO2(%) Mean (±SD) 96.2 (±1.5)
Median (±Interquartile range) 97.0 (±2.0)
Modified shuttle distance
(metres)
Mean (±SD) 1005.4 (±317.0)
Median (±Interquartile range) 1010.0 (±445.0)
BMI (weight in kilograms/
height in metres2)
Mean (±SD) 21.1 (±3.0)
Median (±Interquartile range) 20.5 (±3.7)referred to the Hospital agreed to enter which led to 75 entering
at month 0.
The patients' characteristics are summarised in Table 1. At
baseline the only statistically significant difference was sex.
There were more men than women in each of the groups. When
FEV1 was adjusted for sex, using the mixed model of analysis
of variance, there were no differences among the five treatment
groups (p=0.31). When adjusted for sex using FEV1 as a
percent of predicted FEV1, sex was not a significant predictor.
Using intention to treat, data for the primary outcome
measure were available on 65 of the subjects at the end of the
12-month study period. Fifty-three subjects completed the 12-
month study period on the regimen to which they had been
randomised. Of the 22 patients who did not complete the study,
one had died, one was accepted on to the transplantation list,
one required a limited pleurodesis for a pneumothorax, three
were lost to follow up, three withdrew (one giving no reason
(Cornet), one did not wish to undergo any more tests (Flutter)
and one started a new job outside London (PEP)). Thirteen did
not like the regimen to which they had been randomised and
withdrew either to revert to their original regimen (9) or to a
different one of their choosing (4).3.2. Lung function
There were no significant differences among the regimens in
the primary outcome measure of FEV1 (p=0.35) (Fig. 2).
Overall there was a significant deterioration in FEV1 over the
12-month period (p=0.02). Expressed as change in FEV1
percent predicted, for the group as a whole, this was −1.8%.
There were no significant differences in FVC among the five
groups (p=0.54), MEF25 (p=0.54) or RV%TLC (p=0.24).3.3. Body mass index
There were no significant differences in body mass index
among the five groups (p=0.94).AD n=15 Cornet n=15 Flutter n=15 PEP n=15
25.9 (±6.5)
Range: 17–39
25.3 (±8.3)
Range: 17–49
32.1 (±7.5)
Range: 19–41
29.3 (±12.0)
Range: 18–63
25.0 (±6.0) 24.0 (±8.0) 34.0 (±13.0) 25.0 (±13.0)
Male: 10
66.7%
Male: 8
53.3%
Male: 10
66.7%
Male: 8
53.3%
Female: 5
33.3%
Female: 7
46.7%
Female: 5
33.3%
Female: 7
46.7%
2.6 (± 1.3) 1.9 (± 0.8) 2.4 (± 0.9) 2.1 (± 1.1)
2.4 (±2.3) 1.7 (±1.2) 2.1 (±1.7) 1.8 (±1.5)
96.8 (±2.0) 96.3 (±1.6) 97.2 (±1.8) 96.4 (±1.6)
97.0 (±1.8) 97.0 (±3.0) 97.0 (±3.0) 96.0 (±3.0)
985.0 (±445.9) 906.7 (±311.5) 1044.3 (±292.2) 887.9 (±358.3)
900.0 (±445.0) 930.0 (±350.0) 975.0 (±520.0) 880.0 (±597.5)
22.6 (±3.2) 20.9 (±3.0) 22.8 (±3.1) 21.5 (±3.3)
22.7 (±4.0) 21.5 (±6.0) 22.8 (±3.2) 20.6 (±4.6)
Fig. 2. FEV1 for each regimen. Mean FEV1±SD: ACBT (n=13) at 0 months
2.01±0.82, at 12 months 1.94±0.80; AD (n=13) at 0 months 2.68±1.29, at
12 months 2.64±1.22; Cornet (n=14) at 0 months 1.93±0.87, at 12 months
1.90±0.89; Flutter (n=12) at 0 months 2.46±0.94, at 12 months 2.43±0.94;
PEP (n=13) at 0 months 2.17±1.14, at 12 months 2.02±1.17. There were no
significant differences among the regimens at 0 months or 12 months.
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There were no significant differences in the modified shuttle
test among the five groups (p=0.52).
3.5. Health related quality of life
The Short Form-36 was analysed in the aggregate domains
of physical and mental. There were no significant differences in
the physical domain among the five groups (p=0.99). Overall
there was a trend towards a deterioration over time (p=0.05). In
the mental domain, there were no significant differences among
the five groups (p=0.27) but there was a significant
deterioration over time (p=0.002).
The Chronic Respiratory Questionnaire (CRQ) was ana-
lysed for the four domains of dyspnoea, fatigue, emotion and
mastery. Dyspnoea: There were no significant differences in
dyspnoea among the five groups (p=0.7). Overall there was a
significant improvement over time (p=0.01) in the group as a
whole. Fatigue: There were no significant differences in fatigue
among the 5 groups (p=0.85). Overall there was no significant
difference over time (p=0.69). Emotion: There were no
significant differences in emotion among the five groups
(p=0.39). Overall there was no significant difference over
time (p=0.44). Mastery: There were no significant differences
in mastery among the five groups (p=0.82). Overall there was
no significant difference over time (p=0.37). However there
were clinical, minimal important differences [21] (improve-
ments) in dyspnoea in four of the five groups at 12 months
(Table 2).Table 2
Minimal important differences in the Chronic Respiratory Questionnaire.
Dyspsnoea
ACBT 0–12 months Small improvement (0.7)
AD 0–12 months Small improvement (0.5)
Cornet 0–12 months No difference (b0.5)
Flutter 0–12 months Moderate improvement (1.3)
PEP 0–12 months Small improvement (0.8)
A change of 0.5 represents a small difference in symptoms, 1.0 a moderate
difference and 1.5 a large difference [21].3.6. Intravenous antibiotics
Some patients in each of the regimens required intravenous
antibiotics during the 12-month period. The median number of
courses ranged from 1.0 to 1.5. Owing to the small numbers and
the scattered nature of the data, it was not appropriate to analyse
this data statistically.
4. Discussion
A reduction in FEV1 has been recognised as a predictor of
mortality in people with CF [22] although with improvements in
the management of these people, this is becoming a less
sensitive indicator. Sputum would not have been a valid
outcome measure for a long-term airway clearance study and
more recently available non-invasive measurements had not
been validated at the time of designing the study protocol. Also
at the time of setting up the study protocol, CF disease specific
quality of life questionnaires [23,24] were not in the public
domain. The Short Form-36 was selected as the generic health
related questionnaire and the Chronic Respiratory Disease
Questionnaire as the disease specific questionnaire.
The time for a treatment session was not standardised as the
time required, by an individual with CF, for effective airway
clearance will vary. A longer time for treatment is usually
required during an exacerbation of pulmonary infection and in
the presence of bronchospasm. Standardisation of time is
difficult in a long-term study and would not have reflected
clinical practice. Some people prefer more frequent and shorter
treatment sessions, others longer but less frequent sessions
dependent on life-style.
The assessment of the impact of physiotherapy on lung
disease is difficult in long-term studies as other treatment
strategies in the package of care are continuously under
development [25]. It is well recognised that distinction among
the airway clearance regimens has become blurred in clinical
practice. In this study considerable effort was taken to involve
the original proponents of the regimens in order that the
regimens used in the study were as described and undertaken by
the proponents.
The objective to demonstrate that no one regimen of the
airway clearance techniques of the ACBT, AD, Cornet, Flutter
and PEP was inferior, over a period of one year, was supported
by the results. There were no statistically significant differences,
over the period of 12 months, among the regimens in the
primary outcome measure of FEV1 (p=0.35). Overall there was
a significant deterioration in FEV1 over time (p=0.02), but this
deterioration of −1.8% (as a percent of predicted FEV1) was
within the international average of −2.0% at the time of the
study.
The Short Form-36 identified a significant deterioration in
both the physical (p=0.05) and mental (p=0.002) domains over
time, but there were no significant differences among the
regimens. The Chronic Respiratory Questionnaire identified an
improvement over time in the domain of dyspnoea. The
statistical difference was reflected in the minimal important
difference in all regimens except the Cornet (Table 2). More
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without a corresponding improvement in lung function, or the
subjective sensation of dyspnoea may be influenced by changes
in the subject's internal locus of control.
It was important to monitor closely the lung function in the
subjects on the study as McIlwaine et al. [4] in their long-term
study comparing the airway clearance regimens of PEP and
Flutter had identified, for those on the Flutter regimen, a
reduction in lung function, increased hospitalisation and
increased use of antibiotics after six months. There were no
clinical concerns regarding any of the regimens in the present
study at six months. The differences in outcome between the
two studies may be a reflection of the different age groups, but
this requires further investigation.
Accurso et al. [3] undertook a three-year multi-centre
randomised controlled study to assess the long-term effects of
the airway clearance techniques of postural drainage and
percussion, Flutter and high frequency chest wall oscillation.
It would seem that both single centre and multi-centre airway
clearance trials experience similar problems in recruitment and
retention with long-term studies. High frequency chest wall
oscillation had not been included as one of the regimens of the
current airway clearance study as it was not, at the time,
registered for use as a medical device in Europe.
Which technique for which patient? It was hoped to identify
objective indicators as to which technique should be recom-
mended [26], but none were identified during the study period.
Each regimen can and should be adapted to suit the individual
patient and each patient should be able to adapt his/her regimen
at the time of each treatment session and during a treatment
session. ‘Patient satisfaction and perceived efficacy are
probably intimately related to adherence to a technique’ [26]
and Langenderfer [27] has said, ‘Which alternative to
recommend depends on the ability, motivation, preference,
needs, and resources of each patient.’
This study provides additional evidence for international
practice and concurs with the evidence available, but highlights
the problem of recruitment and retention to long-term studies. It
would have been desirable to have undertaken the study with
larger numbers, but recruitment took place over four years and
with increasing time between the start and finish of a study other
variables begin to bias long-term results, for example changes in
medical management.
The study did not attempt to answer the question as to which
regimen should be used during an acute exacerbation of pulmo-
nary infection. New measurement tools for example lung clear-
ance indices as measurements of ventilation inhomogeneities,
non-invasive chest wall imaging techniques which allow
calculation of lung volumes, lung compliance measurements
and electrical impedance tomographymay provide greater insight
to differences which may exist among the regimens.
5. Conclusion
This study suggests that there are no statistically significant
differences among the airway clearance regimens of the ACBT,
AD, Cornet, Flutter and PEP when used over a period of oneyear, in the sitting position, by adults with cystic fibrosis. It is
likely that to optimise adherence to treatment and consequently
improvements in morbidity and mortality, the patient should be
involved in the selection of his/her airway clearance regimen.
The findings of this study must be limited to people with CF.
The study does not suggest that people with non-CF
bronchiectasis or other conditions with excess bronchial
secretions can effectively use an airway clearance regimen in
the sitting position. Survival and quality of life for people with
CF has improved, but the prognosis is still poor. Gene therapy
and other new treatments may benefit most those with the
minimal lung destruction. Physiotherapy and in particular
airway clearance will therefore remain an important component
in the management of people with CF in the foreseeable future.Acknowledgments
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